(Q40121018)

17 September 2017

Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one (English)

1 reference

17 September 2017

1 reference

Lisa M Ballou

1

1 reference

17 September 2017

Elzbieta S Selinger

2

1 reference

17 September 2017

Jun Yong Choi

3

1 reference

17 September 2017

Dale G Drueckhammer

4

1 reference

17 September 2017

Richard Z Lin

5

1 reference

17 September 2017

language of work or name

English

0 references

publication date

11 June 2007

1 reference

Journal of Biological Chemistry

17 September 2017

1 reference

17 September 2017

282

1 reference

17 September 2017

33

1 reference

17 September 2017

24463-24470

1 reference

An expanding role for mTOR in cancer

17 September 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Activated Gαq Inhibits p110α Phosphatidylinositol 3-Kinase and Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Phosphorylation and activation of p70s6k by PDK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

MAPKAP kinases - MKs - two's company, three's a crowd

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

The serine/threonine kinase Pim-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

TSC2: filling the GAP in the mTOR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Ca(2+)- and phospholipase D-dependent and -independent pathways activate mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

LKB1-dependent signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

PTEN function: how normal cells control it and tumour cells lose it

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

The PIK3CA gene is mutated with high frequency in human breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Phospholipase D confers rapamycin resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M704741200

21 January 2018

Identifiers

DOI

10.1074/JBC.M704741200

1 reference

17 September 2017

1 reference